1. Home
  2. RRBI vs CTNM Comparison

RRBI vs CTNM Comparison

Compare RRBI & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Red River Bancshares Inc.

RRBI

Red River Bancshares Inc.

BUY

Current Price

$90.79

Market Cap

591.3M

ML Signal

BUY

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$14.55

Market Cap

480.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RRBI
CTNM
Founded
1998
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Hotels/Resorts
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
591.3M
480.5M
IPO Year
2019
2024

Fundamental Metrics

Financial Performance
Metric
RRBI
CTNM
Price
$90.79
$14.55
Analyst Decision
Hold
Buy
Analyst Count
1
4
Target Price
N/A
$19.00
AVG Volume (30 Days)
51.9K
271.4K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
1.07%
N/A
EPS Growth
28.89
0.46
EPS
1.81
N/A
Revenue
N/A
N/A
Revenue This Year
$12.72
N/A
Revenue Next Year
$4.35
N/A
P/E Ratio
$14.50
N/A
Revenue Growth
N/A
N/A
52 Week Low
$54.05
$3.35
52 Week High
$98.85
$16.33

Technical Indicators

Market Signals
Indicator
RRBI
CTNM
Relative Strength Index (RSI) 48.52 60.97
Support Level $89.04 $13.86
Resistance Level $92.74 $14.63
Average True Range (ATR) 3.45 0.91
MACD -0.43 0.24
Stochastic Oscillator 50.53 71.17

Price Performance

Historical Comparison
RRBI
CTNM

About RRBI Red River Bancshares Inc.

Red River Bancshares Inc is the bank holding company for the red river bank. The principal business of the Bank is lending and accepting deposits from businesses, professionals, individuals, and public entities. The bank's primary deposit products are demand deposits, savings deposits, and time deposits. The bank maintains a diversified loan portfolio with a focus on commercial real estate (Owner Occupied and Non-Owner Occupied), one-to-four-family residential, commercial, and industrial loans, construction and development Loans, and others. also, provides Treasury Management Services, Private Banking Services, Brokerage Services, and Other Banking Services.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: